Volume 35, Issue 4 pp. 605-607
Clinical Review

Level V in therapeutic neck dissections for papillary thyroid carcinoma

Avi Khafif MD

Corresponding Author

Avi Khafif MD

Head and Neck Surgery and Oncology Unit, A.R.M. Center for Advanced Otolaryngology Head and Neck Surgery, Assuta Medical Center, Tel Aviv, Israel

ENT Clinic, University of Udine, Udine, ItalySearch for more papers by this author
Jesus E. Medina MD

Jesus E. Medina MD

Department of Otorhinolaryngology, The University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma

Search for more papers by this author
K.Thomas Robbins MD, FRCSC

K.Thomas Robbins MD, FRCSC

Division of Otolaryngology–Head and Neck Surgery, Southern Illinois University School of Medicine, Springfield, Illinois

Search for more papers by this author
Carl E. Silver MD

Carl E. Silver MD

Departments of Surgery and Otolaryngology–Head and Neck Surgery, Albert Einstein College of Medicine, Montefiore Medical Center, Bronx, New York

Search for more papers by this author
Randal S. Weber MD

Randal S. Weber MD

Department of Head and Neck Surgery, The University of Texas MD Anderson Cancer Center, Houston, Texas

Search for more papers by this author
Alessandra Rinaldo MD, FRCSEd ad hominem, FRCS (Eng, Ir) ad eundem, FRCSGlasg

Alessandra Rinaldo MD, FRCSEd ad hominem, FRCS (Eng, Ir) ad eundem, FRCSGlasg

ENT Clinic, University of Udine, Udine, Italy

Search for more papers by this author
Randall P. Owen MD, MS

Randall P. Owen MD, MS

Department of Surgery, Division of Metabolic, Endocrine and Minimally Invasive Surgery, Mount Sinai School of Medicine, New York, New York

Search for more papers by this author
Ashok R. Shaha MD

Ashok R. Shaha MD

Head and Neck Service, Memorial Sloan-Kettering Cancer Center, New York, New York

Search for more papers by this author
Alfio Ferlito MD, DLO, DPath, FRCSEd ad hominem, FRCS (Eng, Glasg, Ir) ad eundem, FDSRCS ad eundem, FHKCORL, FRCPath, FASCP, IFCAP

Corresponding Author

Alfio Ferlito MD, DLO, DPath, FRCSEd ad hominem, FRCS (Eng, Glasg, Ir) ad eundem, FDSRCS ad eundem, FHKCORL, FRCPath, FASCP, IFCAP

ENT Clinic, University of Udine, Udine, Italy

ENT Clinic, University of Udine, Udine, ItalySearch for more papers by this author
First published: 27 January 2012
Citations: 21

Abstract

Neck dissection for papillary thyroid carcinoma (PTC) is the standard of care for patients with clinical evidence of regional metastases. However, the extent of neck dissection is debatable. The purpose of the current study was to develop evidence-based recommendations for when to include level V, or 1 of its sublevels, among patients with PTC undergoing neck dissection. A literature review of all studies evaluating the occurrence of metastases in level V in patients with regional metastases from PTC undergoing neck dissection was performed. Occurrence of metastases at level V is low in most series (5% to 10%), although a wide range was noticed. In cases in which metastases were found at level V, they occurred almost exclusively at sublevel VB. Sublevel VA was rarely, if ever, involved with metastatic lymph nodes. However, only recently have investigators begun to specify which sublevels of level V are at risk. Therapeutic dissection of level V is indicated when there is clinical evidence of disease involving this zone. Elective dissection of sublevel VB is indicated when there is involvement of level IV, or possibly multiple nodes at levels II and III. Under these circumstances, dissection of sublevel VB is indicated but sublevel VA may be spared. © 2012 Wiley Periodicals, Inc. Head Neck, 2013

The full text of this article hosted at iucr.org is unavailable due to technical difficulties.